<ul>
<li>Edesa Biotech will present new exploratory clinical data on paridiprubart in acute kidney injury at the 63rd European Renal Association Congress in Glasgow on June 3-6, 2026.     *      The analysis draws from a study in patients with respiratory distress who also developed acute kidney injury, a complication with no approved targeted treatments.     *      The company has pointed to Phase 3 findings showing a consistent, statistically significant reduction in mortality in acute kidney injury patients, supporting a potential path toward a targeted therapy.     *      An oral presentation is scheduled for June 5, 2026 at 4:30 p.m. local time, with additional analyses also planned for release during the meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190915PRIMZONEFULLFEED9722569) on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

EDSA

SBIO

IBBQ

<p>Edesa Biotech will present new clinical data on paridiprubart for acute kidney injury at the 63rd European Renal Association Congress in Glasgow from June 3-6, 2026. The analysis indicates a significant reduction in mortality among patients with acute kidney injury, suggesting a potential targeted therapy. An oral presentation is scheduled for June 5, 2026.</p>

PUBT

Edesa Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Edesa Biotech presents new paridiprubart acute kidney injury data at ERA Congress